Summit Therapeutics PLC (SMMT) stock surged 6.69% in pre-market trading on Monday, fueled by the announcement of a clinical trial collaboration with Pfizer Inc. (PFE) to evaluate its investigational bispecific antibody, ivonescimab, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
The collaboration aims to accelerate the development of potentially transformative combination therapies by evaluating ivonescimab, a novel PD-1/VEGF bispecific antibody, alongside Pfizer's innovative vedotin ADCs. The goal is to explore the clinical synergy of these therapies and potentially improve the standard of care for patients with serious unmet needs in various solid tumor types.
Under the agreement, Summit will provide ivonescimab for the proposed studies, while Pfizer will be responsible for conducting the operations. The studies, planned to begin in the middle of this year, will be overseen by both companies. Further details on the clinical trials will be announced at a later date.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。